STLN
SinkerThe Oncology Institute, Inc. · Healthcare · United States · $684M cap · $10.1M/day traded
$3.75 -10.7% · close 12 Nov · scored 13 Nov
Score down 4.5 since 12 Nov: Momentum down 6 after a 11% price fall.
Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.
As of 13 Nov 2026, the MoatMap Score for The Oncology Institute, Inc. (STLN) is 33/100, ranked against 25,000+ stocks in 38 markets (Quality 46, Value 32, Momentum 45, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT THE ONCOLOGY INSTITUTE, INC.
Read
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 252.5M | 324.2M | 393.4M | 502.7M | 25.8% | 620.4M | 665.0M | 883.9M | 32.6% |
| EPS | 0.02 | -0.92 | -0.71 | -0.54 | — | -0.28 | -0.16 | — | — |
| Shares | 73.3M | 74.1M | 75.7M | 98.9M | +34.9% | 101.9M | — | — | — |
| Debt | 108.2M | 119.7M | 123.2M | 103.7M | -1.4% | 102.8M | — | — | — |
| Equity | 123.2M | 57.0M | 3.6M | -15.7M | -82.9% | — | — | — | — |
| Op CF | -61.8M | -36.3M | -26.5M | -24.6M | — | 23.1M | — | — | — |
| Inv CF | -131.6M | 62.6M | 46.2M | -3.1M | — | — | — | — | — |
| Fin CF | 92.2M | -6.8M | -3.5M | 11.6M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 93% of stocks we rank over the past year (volatility 94% a year).
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend: It is near its 52-week high and above its 200-day average.
- No clear trend (this stock): None of the above: no recent deep fall and no steady climb.
- No read yet: Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STLN are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| STLN | The Oncology Institute, Inc.(you) | $684M | 33 |
| SNDA | Sonida Senior Living, Inc. | $1.6B | 30 |
| SRTA | Strata Critical Medical, Inc. | $412M | 45 |
| AGL | agilon health, inc. | $1.5B | 42 |
| PIII | P3 Health Partners Inc. | $844M | 10 |
| PNTG | The Pennant Group, Inc. | $1.5B | 54 |
| BKD | Brookdale Senior Living Inc. | $2.4B | 21 |
| CYH | Community Health Systems, Inc. | $412M | 63 |
| GMRS | GMR Solutions Inc. | $580M | 73 |
| USPH | U.S. Physical Therapy, Inc. | $1.3B | 65 |
Peer medians: ROE -30.5% · P/E 25.9x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.